Personalized Medicine Market Analysis 2023by Vijay K. Web Marketing
The global personalized medicine market is expected to witness significant growth due rapid advancement in diagnostic techniques, population heterogeneity across the globe, increasing awareness about the benefits of genetic makeup based drugs, and improving quality of disease diagnosis. The key vendors in the global personalized medicine market are focusing on oncology, infectious disease and cardiovascular targeted treatment and diagnostics.
Browse report sample at: https://www.psmarketresearch.com/market-analysis/personalized-medicine-market/report-sample
The pharmaceutical companies and biotechnology companies are actively involved in the research and development of personalized medicine. Different companies are developing and manufacturing biologics, such as blood products, vaccines, nutritional products, and gene therapies, to improve the quality of patient life. In December 2014, U.S. Food and Drug Administration (FDA) approved Lynparza, a poly (ADP-ribose) polymerase inhibitor as monotherapy in patients with deleterious or suspected deleterious germline breast cancer mutated advanced ovarian cancer, who have been treated with three or more prior lines of chemotherapy. Also in the same year, the organization approved the VIMIZIM, an enzyme replacement therapy for the treatment of patients with Morquio A syndrome.
Recent development in pharmacogenomics for the benefits of patient population and increasing involvement of pharmaceutical companies for the development of personalized medicine are driving growth of the global personalized medicine market. Implementation of the favorable government policies for personalized medicine is also creating huge traction for the development of personalized medicines. However, complex nature of the personalized drugs and high cost associated with the research and development act as key barriers for growth of the global market.
Some of the key players operating in the global personalized medicine market are GE Healthcare, Illumina Inc., Quest Diagnostics Incorporated, Abbott, Affymetrix, Inc., Bayer AG, F. Hoffmann-La Roche AG, AstraZeneca PLC, Pfizer Inc., Valeant Pharmaceuticals International, Inc., and Vertex Pharmaceuticals Incorporated.
Created on Jan 23rd 2019 02:37. Viewed 177 times.
No comment, be the first to comment.